Literature DB >> 32701354

Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer.

R C Zou1, Z T Guo1, D Wei1, Z T Shi1, Z C Ye1, G Zhai1, C Zhong1, B Tang1, L Wang1, J Y Ge1.   

Abstract

Downregulation of cell division cycle-associated 3 (CDCA3) markedly inhibited cell growth and induced apoptosis in tumors. However, the effect of CDCA3 in pancreatic cancer (PAC) was rarely investigated. Therefore, this study attempted to clarify the role of CDCA3 in PAC. The mRNA and protein expression of CDCA3 were examined in PAC cell lines and tumor tissues by using real-time quantitative PCR (RT-qPCR), western blotting (WB), and immunohistochemistry (IHC). The effects of CDCA3 downregulation on cell proliferation, apoptosis, and colony information were investigated through MTT assay, Annexin V-APC single staining cell apoptosis detection, and colony formation test. The microarray and ingenuity pathway analysis were employed to explore the potential regulatory relation. The tumor xenograft model was established for determining the effect of CDCA3 downregulation on the growth of PAC in vivo. The results showed that the expression of CDCA3 in tumor tissues was higher than that of normal tissues (p<0.05). In addition, the mRNA expression of CDCA3 was markedly increased in PANC-1 cells and SW 1990 cells when compared with human pancreatic duct epithelial (HPDE) cells (p<0.05). MTT assay showed that the cell proliferation of PANC-1 cells and SW 1990 cells was significantly inhibited after the lentivirus transfection of CDCA3 knockdown (p<0.05). Annexin V-APC apoptosis assays suggested that the apoptotic cell number was markedly increased in the shCDCA3 group compared to that in the shCtrl group in SW 1990 cells and PANC-1 cells (p<0.05). Meanwhile, the activity of caspase-3/7 was obviously elevated in the shCDCA3 group compared to the shCtrl group (p<0.05). The colony formation was notably inhibited in the shCDCA3 group relative to the shCtrl group in SW 1990 cells (p<0.05). Moreover, the tumor growth was evidently suppressed in the shCDCA3 group compared with the shCtrl group in vivo (p<0.05). These findings revealed that CDCA3 plays a crucial role in the progress of PCA by regulating cell apoptosis and proliferation, which may serve as a potential target for PAC treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32701354     DOI: 10.4149/neo_2020_200411N388

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3.

Authors:  Junpeng Ji; Huibing Li; Jing Chen; Wenjun Wang
Journal:  Int J Mol Med       Date:  2022-07-01       Impact factor: 5.314

2.  CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma.

Authors:  Zhihuai Wang; Shuai Chen; Gaochao Wang; Sun Li; Xihu Qin
Journal:  Biomed Res Int       Date:  2021-01-29       Impact factor: 3.411

3.  Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma.

Authors:  Chen Xing; Zhenglin Wang; Yating Zhu; Chao Zhang; Miao Liu; Xianyu Hu; Wei Chen; Yinan Du
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

4.  The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma.

Authors:  Dexin Shen; Yayun Fang; Fenfang Zhou; Zhao Deng; Kaiyu Qian; Gang Wang; Yu Xiao; Lingao Ju; Xinghuan Wang
Journal:  Cancer Cell Int       Date:  2021-05-12       Impact factor: 5.722

5.  Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation.

Authors:  Peng Gu; Minhao Zhang; Jin Zhu; Xiaoliang He; Dongrong Yang
Journal:  Oncol Rep       Date:  2021-12-31       Impact factor: 3.906

Review 6.  Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.

Authors:  Yingkun Xu; Meiying Shen; Yang Peng; Li Liu; Lingfeng Tang; Ting Yang; Dongyao Pu; Wenhao Tan; Wenjie Zhang; Shengchun Liu
Journal:  Biomed Res Int       Date:  2022-08-30       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.